Drug Trial Radar · NCT07410494
Biomarker-Guided Allogeneic Single-Target or Dual-Target CAR-NK Cell Therapy for Advanced Solid Tumors
Last checked: Nov 20, 2026Latest source record: Feb 18, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
85
Planned (sponsor's estimate)
Start
Feb 1, 2026
Primary completion
Dec 28, 2027
Study completion Dec 28, 2028
Sponsor
- Lead sponsor
- Essen BiotechAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Feb 13, 2026
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 8 years, up to 85 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This Phase 1/2 study evaluates the safety, feasibility, and preliminary anti-tumor activity of allogeneic donor-derived CAR-NK cells in participants with advanced solid tumors. The CAR target antigen is selected for each participant after tumor profiling using a tissue biopsy and/or liquid biopsy. Participants will receive either a single-target or dual-target CAR-NK product based on the antigen profile.
Conditions
- Cancer
- Breast Cancer
- Non-Small Cell Lung Cancer (NSCLC)
- Colorectal Cancer (Locally Advanced or Metastatic)
- Prostate Cancer - Recurrent
- Pancreatic Ductal Adenocarcinoma (PDAC)
- Ovarian Cancer
- Glioblastoma
- Melanoma (Skin Cancer)
- Acute Myeloid Leukemia (AML)
- Non Hodgkin Lymphoma
- Multiple Myeloma (MM), Lymphoma, Large B-Cell, Diffuse (DLBCL), Lymphoma
- Liver Cancer
Interventions
EB-SELECT Single-Target CAR-NK CellsBiological
Donor-derived CAR-NK cells expressing a single CAR selected from the target menu. WITH Fludarabine (IV) + Cyclophosphamide (IV), administered prior to CAR-NK infusion. Similar conditioning drugs are used in CAR-NK solid tumor trials.
Dual-Target Antigen-Selected CAR-NKBiological
Participants whose profiling identifies two actionable antigens, or strong evidence of antigen heterogeneity. WITH Fludarabine (IV) + Cyclophosphamide (IV), administered prior to CAR-NK infusion . Similar conditioning drugs are used in CAR-NK solid tumor trials.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence, type, and severity of adverse events (AEs), graded by CTCAE v5.0Time frame: 28 DAYS
- Incidence of Dose-Limiting Toxicities (DLTs)Time frame: 28 DAYS
Locations
1 site in 1 country. Site status is shown where the registry gives one.
District One Hospital
Beijing, Beijing Municipality, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.